Cost-effectiveness analysis of systematic fast-track transition from oncological treatment to specialised palliative care at home for patients and their caregivers: the DOMUS trial

被引:10
|
作者
Halling, Christine Marie Baeko [1 ]
Wolf, Rasmus Trap [1 ]
Sjogren, Per [2 ,3 ]
Von der Maase, Hans [2 ,3 ]
Timm, Helle [4 ]
Johansen, Christoffer [2 ,5 ]
Kjellberg, Jakob [1 ]
机构
[1] VIVE Danish Ctr Social Sci Res, Herluf Trolles Gade 11, DK-1052 Copenhagen K, Denmark
[2] Copenhagen Univ Hosp, Dept Oncol, Rigshosp, Copenhagen, Denmark
[3] Univ Copenhagen, Fac Hlth & Med Sci, Copenhagen, Denmark
[4] REHPA Danish Knowledge Ctr Rehabil & Palliat Care, Copenhagen, Denmark
[5] Danish Canc Soc, Copenhagen, Denmark
关键词
Cancer; Informal Care; Economic evaluation; Effectiveness; Utility; QALY; Accelerated; Palliative care; Psychological intervention; PREFERENCE-BASED MEASURE; WILLINGNESS-TO-PAY; INFORMAL CARE; EFFECTIVENESS THRESHOLD; CANCER-PATIENTS; DEATH; HEALTH; PLACE; VALUATION; CHOICE;
D O I
10.1186/s12904-020-00645-7
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: While hospitals remain the most common place of death in many western countries, specialised palliative care (SPC) at home is an alternative to improve the quality of life for patients with incurable cancer. We evaluated the cost-effectiveness of a systematic fast-track transition process from oncological treatment to SPC enriched with a psychological intervention at home for patients with incurable cancer and their caregivers. Methods: A full economic evaluation with a time horizon of six months was performed from a societal perspective within a randomised controlled trial, the DOMUS trial (: NCT01885637). The primary outcome of the health economic analysis was a incremental cost-effectiveness ratio (ICER), which is obtained by comparing costs required per gain in Quality-Adjusted Life Years (QALY). The costs included primary and secondary healthcare costs, cost of intervention and informal care from caregivers. Public transfers were analysed in seperate analysis. QALYs were measured using EORTC QLQ-C30 for patients and SF-36 for caregivers. Bootstrap simulations were performed to obtain the ICER estimate. Results: In total, 321 patients (162 in intervention group, 159 in control group) and 235 caregivers (126 in intervention group, 109 in control group) completed the study. The intervention resulted in significantly higher QALYs for patients when compared to usual care (p-value = 0.026), while being more expensive as well. In the 6 months observation period, the average incremental cost of intervention compared to usual care was euro2015 per patient (pvalue < 0.000). The mean incremental gain was 0.01678 QALY (p-value = 0.026). Thereby, the ICER was euro118,292/QALY when adjusting for baseline costs and quality of life. For the caregivers, we found no significant differences in QALYs between the intervention and control group (p-value = 0.630). At a willingness to pay of euro80,000 per QALY, the probability that the intervention is cost-effective lies at 15% in the base case scenario. Conclusion: This model of fast-track SPC enriched with a psychological intervention yields better QALYs than usual care with a large increase in costs.
引用
收藏
页数:13
相关论文
共 29 条
  • [21] Cost-effectiveness of 12 weeks of supervised treatment compared to written advice in patients with knee osteoarthritis: a secondary analysis of the 2-year outcome from a randomized trial
    Skou, S. T.
    Roos, E. M.
    Laursen, M.
    Arendt-Nielsen, L.
    Rasmussen, S.
    Simonsen, O.
    Ibsen, R.
    Larsen, A. T.
    Kjellberg, J.
    OSTEOARTHRITIS AND CARTILAGE, 2020, 28 (07) : 907 - 916
  • [22] LONG-TERM COST-EFFECTIVENESS ANALYSIS OF TICAGRELOR IN PATIENTS WITH ACUTE CORONARY SYNDROME (ACS) FROM A MEXICAN PUBLIC AND PRIVATE HEALTH CARE PERSPECTIVE BASED ON DATA FROM THE PLATO TRIAL
    Garcia-Castillo, A.
    De-los-Rios, M.
    Polanco, A. C.
    Ramirez, M. A.
    Nikolic, E.
    Mellstrom, C.
    VALUE IN HEALTH, 2011, 14 (07) : A379 - A380
  • [23] TICAGRELOR TREATMENT FOR PREVENTION OF CARDIOVASCULAR EVENTS IN HIGH RISK POST MYOCARDIAL INFARCTION PATIENTS: COST-EFFECTIVENESS ANALYSIS USING EVIDENCE FROM THE PEGASUS-TIMI 54 TRIAL
    Moore, P.
    Briggs, A.
    Davies, A.
    Sculpher, M.
    Kun, K.
    Magnuson, E. A.
    Cohen, D. J.
    Mellstrom, C.
    VALUE IN HEALTH, 2016, 19 (07) : A655 - A655
  • [24] AN EARLY COST-EFFECTIVENESS ANALYSIS OF ABELACIMAB VERSUS RIVAROXABAN, A STANDARD OF CARE DIRECT ORAL ANTICOAGULANT (DOAC), IN PATIENTS WITH ATRIAL FIBRILLATION USING PRELIMINARY RESULTS FROM THE AZALEA-TIMI 71 TRIAL
    Benner, J.
    Li-Mcleod, J.
    Bloomfield, D.
    Ellis, A.
    VALUE IN HEALTH, 2024, 27 (06) : S65 - S65
  • [25] Using informative prior based on expert opinion in Bayesian estimation of the transition probability matrix in Markov modelling—an example from the cost-effectiveness analysis of the treatment of patients with predominantly negative symptoms of schizophrenia with cariprazine
    Zoltán Vokó
    István Bitter
    Beatrix Mersich
    János Réthelyi
    Anett Molnár
    János G. Pitter
    Árpád Götze
    Margit Horváth
    Kristóf Kóczián
    Laura Fonticoli
    Filippo Lelli
    Bertalan Németh
    Cost Effectiveness and Resource Allocation, 18
  • [26] Cost-effectiveness of a nurse facilitated, cognitive behavioural self-management programme compared with usual care using a CBT Manual alone for patients with heart failure: secondary analysis of data from the SEMAPHFOR trial
    Mejia, Aurelio
    Richardson, Gerry
    Pattenden, Jill
    Cockayne, Sarah
    Lewin, Robert
    INTERNATIONAL JOURNAL OF NURSING STUDIES, 2014, 51 (09) : 1214 - 1220
  • [27] Using informative prior based on expert opinion in Bayesian estimation of the transition probability matrix in Markov modelling-an example from the cost-effectiveness analysis of the treatment of patients with predominantly negative symptoms of schizophrenia with cariprazine
    Voko, Zoltan
    Bitter, Istvan
    Mersich, Beatrix
    Rethelyi, Janos
    Molnar, Anett
    Pitter, Janos G.
    Gotze, Arpad
    Horvath, Margit
    Koczian, Kristof
    Fonticoli, Laura
    Lelli, Filippo
    Nemeth, Bertalan
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2020, 18 (01)
  • [28] THE CLINICAL EFFICACY AND COST-EFFECTIVENESS OF BOCEPREVIR IN COMBINATION WITH PEGYLATED INTERFERON- ALFA AND RIBAVIRIN FOR THE TREATMENT OF GENOTYPE 1 CHRONIC HEPATITIS C PATIENTS: A WITHIN TRIAL ANALYSIS FROM THE PERSPECTIVE OF THE SCOTTISH NATIONAL HEALTH SERVICE (NHS)
    Nikoglou, E.
    Humphreys, S.
    El Khoury, A.
    Ferrante, S. A.
    O' Regan, C.
    VALUE IN HEALTH, 2011, 14 (07) : A274 - A274
  • [29] Cost-Effectiveness Analysis of Camrelizumab Plus Chemotherapy vs. Chemotherapy Alone as the First-Line Treatment in Patients With IIIB-IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Without EGFR and ALK Alteration from a Perspective of Health-Care System in China
    Zhu, Chen
    Xing, Xiao-xuan
    Wu, Bin
    Liang, Gang
    Han, Gang
    Lin, Cai-xia
    Fang, Hong-mei
    FRONTIERS IN PHARMACOLOGY, 2021, 12